

Lipid-Based Medications and Conventional Counterparts

Scope: Unless otherwise stated, these items pertain only to drugs available in both lipid-based and conventional formulations, including amphotericin B, bupivacaine, cytarabine, **DOXO**rubicin, irinotecan, and vin**CRIS**tine.

Self-Assessment Items

A	There has been no activity to implement this item.
B	This item has been formally discussed and considered, but it has not been implemented.
C	This item has been partially implemented for some or all patients, orders, drugs, or staff.
D	This item is fully implemented for some patients, orders, drugs, or staff.
E	This item is fully implemented for all patients, orders, drugs, or staff.

		A	B	C	D	E
Products Used						
1	Whenever possible, only the lipid-based or the conventional formulation of a drug (not both) is available on formulary or used (e.g., only the lipid-based formulation of amphotericin B is on formulary or used) to reduce the risk of confusion between these products.					
Storage						
2	Drugs available in both lipid-based and conventional formulations are stocked only in the pharmacy and dispensed for specific patients as prescribed. Exception: <i>Bupivacaine (including Exparel) may be part of anesthesia stock outside the pharmacy.</i>					
3	Lipid-based and conventional formulations of the same drug are stored in different bins that are physically separated.					
4	Lipid-based formulations of different drugs are not stored together or next to each other.					
Product Labeling						
5	Clearly visible cautionary labels are affixed to lipid-based product containers to differentiate them from conventional forms of drugs.					
Technology Alerts						
6	The computer order entry system performs dose range checks when entering all lipid-based drugs or their conventional counterparts to warn practitioners if the wrong formulation or dose has been prescribed or selected.					
7	When a dosing deviation has been detected by a computer order entry system, the system requires a HARD STOP verification that the correct formulation of the drug has been selected.					

A	There has been no activity to implement this item.
B	This item has been formally discussed and considered, but it has not been implemented.
C	This item has been partially implemented for some or all patients, orders, drugs, or staff.
D	This item is fully implemented for some patients, orders, drugs, or staff.
E	This item is fully implemented for all patients, orders, drugs, or staff.

		A	B	C	D	E
Product Differentiation						
8	Lipid-based drugs and their conventional counterparts are communicated using brand names (if available) and generic names, or just brand names if space is limited, to differentiate them in the following applications: (score each item individually)					
a	Protocols, guidelines, and order sets					
b	Drug fields in prescriber computer order entry systems					
c	Drug fields in pharmacy computer order entry systems					
d	Pharmacy labels and/or AUTOMATED SYSTEM LABELS					
e	Storage bin/shelf labels					
f	ADC screens					
g	MARs/eMARs					
h	Drug fields on SMART INFUSION PUMP screens					
Staff Competency and Education						
9	Practitioners who may prescribe, dispense, or administer lipid-based drugs and/or conventional counterparts have been educated about the differences between these formulations and the risk of patient harm if these products are confused with each other.					